Phase I Study Of Prolonged Low Dose Decitabine (5-Aza-Deoxycitidine, NSC # 127716) In Patients With Biopsiable Advanced Cancers Refractory To Standard Therapy

Trial Profile

Phase I Study Of Prolonged Low Dose Decitabine (5-Aza-Deoxycitidine, NSC # 127716) In Patients With Biopsiable Advanced Cancers Refractory To Standard Therapy

Discontinued
Phase of Trial: Phase I

Latest Information Update: 04 Jan 2013

At a glance

  • Drugs Decitabine (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 04 Jan 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 20 Oct 2009 Planned number of patients changed from 24 to 36 as reported by ClinicalTrials.gov.
    • 17 Apr 2008 Status changed from recruiting to completed according to clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top